Literature DB >> 25023394

Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.

Ke Wang1, Xiaofeng Zhang2, Yang Liu3, Chang Liu2, Baohong Jiang4, Yanyan Jiang5.   

Abstract

Tumor-penetrating peptide, iRGD (internalizing RGD, CRGDK/RGPD/EC) with the similar affinity to αv integrins as conventional RGD cyclopeptide could enhance the tumor penetrability of drugs by binding to neuropilin-1 (NRP-1) that over-expressed on both angiogenic blood vessels and tumor cells. Comparing with our previous study, in which a RGD cyclopeptide (RGDyC) was bound to PEGylated polyamidoamine (PAMAM) dendrimer with doxorubicin (DOX) by acid-sensitive cis-aconityl linkage (PEG-PAMAM-cis-aconityl-DOX, PPCD), the present study selected iRGD instead of previous RGD to produce iRGD-PPCD conjugate. The effect of iRGD-mediated PPCD on tumor penetration was compared with the conventional RGD ones via administration of RGDs-modified PPCD (iRGD/RGDs-PPCD) and co-administration of RGDs and PPCD (iRGD/RGD + PPCD). C6 cells were selected as the cell model owing to the highest expression of αv integrins and NRP-1 among four tumor cell lines. In vitro cytotoxicity and cellular uptake showed no significant difference between RGD-PPCD and iRGD-PPCD, but glioma spheroid penetration study showed that RGD-PPCD, iRGD-PPCD and iRGD + PPCD penetrated into C6 spheroids with a depth of 115 μm, 144 μm and 150 μm, respectively, indicating that the iRGD-mediated PPCD delivery system had a stronger penetrating ability than the RGD ones. In vivo results also demonstrated the superiority of iRGD system over RGD ones. After systemic administration, iRGD-mediated PPCD increased tumor vascular permeability, decreased tumor vascular density and average vascular diameter. Correspondingly, the iRGD system exhibited stronger penetration ability, higher accumulation in brain tumor. The median survival time of iRGD + PPCD, iRGD-PPCD and RGD-PPCD treatment groups were 61, 57.5 and 43.5 days. The present findings strongly suggested that the iRGD-mediated drug delivery system could significantly improve the efficacy of tumor therapy through enhancing tumor accumulation and penetration as compared to the conventional RGD ones.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Co-administration; Conjugates; Tumor vascular permeability; Tumor-penetrating peptide; iRGD

Mesh:

Substances:

Year:  2014        PMID: 25023394     DOI: 10.1016/j.biomaterials.2014.06.042

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  32 in total

1.  Uniform brain tumor distribution and tumor associated macrophage targeting of systemically administered dendrimers.

Authors:  Fan Zhang; Panagiotis Mastorakos; Manoj K Mishra; Antonella Mangraviti; Lee Hwang; Jinyuan Zhou; Justin Hanes; Henry Brem; Alessandro Olivi; Betty Tyler; Rangaramanujam M Kannan
Journal:  Biomaterials       Date:  2015-03-18       Impact factor: 12.479

2.  iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes.

Authors:  Lorena Simón-Gracia; Hedi Hunt; Pablo Scodeller; Jens Gaitzsch; Venkata Ramana Kotamraju; Kazuki N Sugahara; Olav Tammik; Erkki Ruoslahti; Giuseppe Battaglia; Tambet Teesalu
Journal:  Biomaterials       Date:  2016-07-20       Impact factor: 12.479

3.  Targeted drug delivery using iRGD peptide for solid cancer treatment.

Authors:  Xiangsheng Liu; Jinhong Jiang; Ying Ji; Jianqin Lu; Ryan Chan; Huan Meng
Journal:  Mol Syst Des Eng       Date:  2017-08-16

4.  A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis.

Authors:  Kazuki N Sugahara; Pablo Scodeller; Gary B Braun; Tatiana Hurtado de Mendoza; Chisato M Yamazaki; Michael D Kluger; Joji Kitayama; Edwin Alvarez; Stephen B Howell; Tambet Teesalu; Erkki Ruoslahti; Andrew M Lowy
Journal:  J Control Release       Date:  2015-06-11       Impact factor: 9.776

5.  iRGD-functionalized PEGylated nanoparticles for enhanced colon tumor accumulation and targeted drug delivery.

Authors:  Lijun Ma; Qiubing Chen; Panpan Ma; Moon Kwon Han; Zhigang Xu; Yuejun Kang; Bo Xiao; Didier Merlin
Journal:  Nanomedicine (Lond)       Date:  2017-07-26       Impact factor: 5.307

6.  NRP1 transport of cancer therapeutics mediated by tumor-penetrating peptides.

Authors:  Qixin Leng; Martin C Woodle; A James Mixson
Journal:  Drugs Future       Date:  2017-02       Impact factor: 0.148

7.  Tumor-Penetrating Nanosystem Strongly Suppresses Breast Tumor Growth.

Authors:  Shweta Sharma; Venkata Ramana Kotamraju; Tarmo Mölder; Allan Tobi; Tambet Teesalu; Erkki Ruoslahti
Journal:  Nano Lett       Date:  2017-02-17       Impact factor: 11.189

8.  Competition of charge-mediated and specific binding by peptide-tagged cationic liposome-DNA nanoparticles in vitro and in vivo.

Authors:  Emily Wonder; Lorena Simón-Gracia; Pablo Scodeller; Ramsey N Majzoub; Venkata Ramana Kotamraju; Kai K Ewert; Tambet Teesalu; Cyrus R Safinya
Journal:  Biomaterials       Date:  2018-03-02       Impact factor: 12.479

9.  Co-Administration Of iRGD Enhances Tumor-Targeted Delivery And Anti-Tumor Effects Of Paclitaxel-Loaded PLGA Nanoparticles For Colorectal Cancer Treatment.

Authors:  Yi Zhong; Tao Su; Qiuxiao Shi; Yanru Feng; Ze Tao; Qiuxia Huang; Lan Li; Liqiang Hu; Shengfu Li; Hong Tan; Shan Liu; Hao Yang
Journal:  Int J Nanomedicine       Date:  2019-11-01

10.  Antitumor Activity of Thermosensitive Hydrogels Packaging Gambogic Acid Nanoparticles and Tumor-Penetrating Peptide iRGD Against Gastric Cancer.

Authors:  Dinghu Zhang; Yanhong Chu; Hanqing Qian; Lingyu Qian; Jie Shao; Qiuping Xu; Lixia Yu; Rutian Li; Quanan Zhang; Fenglei Wu; Baorui Liu; Qin Liu
Journal:  Int J Nanomedicine       Date:  2020-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.